Eli Lilly and Company (LLY)
| Market Cap | 929.09B +18.9% |
| Revenue (ttm) | 65.18B +44.7% |
| Net Income | 20.64B +94.9% |
| EPS | 22.95 +96.0% |
| Shares Out | 893.36M |
| PE Ratio | 45.32 |
| Forward PE | 30.34 |
| Dividend | $6.92 (0.67%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2,697,930 |
| Open | 1,039.98 |
| Previous Close | 1,034.81 |
| Day's Range | 1,033.69 - 1,064.34 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 1,155.33 (+11.09%) |
| Earnings Date | Feb 4, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,155.33, which is an increase of 11.09% from the latest price.
News
Is LLY Stock Headed To $1,350?
Following record-breaking adoption of its GLP-1 portfolio and positive Phase 3 data in Alzheimer's treatments, LLY has entered a new growth tier. Our multi-factor analysis suggests now is an opportune...
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration ...
Baron Opportunity Fund Q4 2025 Contributors And Detractors
SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Eli Lilly shares contributed to performance as Zepbound continues to gain share for the treatment of ...
What Will Drive Eli Lilly Stock's Next Breakout?
Eli Lilly stock (NYSE: LLY) has been on a tear, surging over 60% in just the last six months. This momentum is part of a broader pattern of explosive growth; the stock has repeatedly rallied more than...
Lilly's bowel disease drug gets approval in China
Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel disease, expanding the treatment's use to the world's second-largest pharmaceutical market, it said on W...
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments
The strategic move is seen as a significant step in enhancing Lilly's capabilities in genetic medicine, adding pressure as broader markets edged lower.
Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion
Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.
Eli Lilly Stock Rises. It's Acquiring This Cell Therapy Company for $2.4 Billion.
Lilly agrees to acquire Orna Therapeutics in an all-cash deal.
Lilly to buy Orna Therapeutics for up to $2.4 billion
Eli Lilly will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term inn...
Innovent Biologics Strikes Partnership Deal With Eli Lilly
Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.
China's Innovent clinches new Lilly deal for immunology, cancer drug development
China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and as much as $8.5 billion more ...
LLY Gains on NVO Losses & Outlook for Weight Loss Drug Trade
Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originall...
Weight-loss drugs to compete on biggest stage with Super Bowl ads
Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its prom...
Eli Lilly: Positives Outweigh The Concerns
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite ...
Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly
Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ...
Eli Lilly's 2026 Outlook Push Back Demand Fears: Analyst
Eli Lilly and Co. (NYSE: LLY) stock is trading lower on Thursday, possibly on profit-taking after the stock rallied roughly 10% on Wednesday.
LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic
After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he...
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1.
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock...
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez
Seamus Fernandez, Guggenheim managing director, joins 'Power Lunch' to discuss the battle between Novo Nordisk and Eli Lilly.
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging a...